
    
      This has been an ongoing area of interest by our group at the Univ. of Minnesota, but this is
      a new protocol to take the place of several older protocols. While survival has been very
      good on the prior protocols over the past decade, incomplete engraftment has remained
      somewhat problematic. Therefore, we have modified the preparative regimen somewhat to
      increase engraftment by replacing anti-thymocyte globulin (ATG) with Campath-1H, a drug that
      is more immune suppressive. In addition, we have modified the supportive care regimen. Based
      on this, we will monitor levels of an anti-oxidant therapy (N-acetylcysteine) and biomarkers
      of inflammation and oxidative stress for the families that consent to these research studies.
    
  